✔ COMPLIANT
★★☆
Biotechnology & Medical Research | USA
Business: PASS
Heat Biologics Inc has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.
Financials: PASS
The financials pass two standards and fail in one.
FTSE
| Debt/A | 0.22% | ✔ |
| Cash/A | 8.8% | ✔ |
| (AR+C)/A | 8.8% | ✔ |
AAOIFI
| Debt/MC | 0.37% | ✔ |
| Cash/MC | 138.8% | ✘ |
DJIM
| Debt/24MC | 0.19% | ✔ |
| Cash/24MC | 7.82% | ✔ |
| AR/24MC | % |
Total Analysts: 5
Recommendation Rating
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Low: 8
High: 33
| Market cap | 72654064 |
| Assets | 124194640 |
| Dividends per Share | |
| Revenue Growth | -3.3 |
Heat Biologics, Inc. is a biopharmaceutical company primarily engaged in the development of immune therapies and vaccines. Its gp96 platform is designed to activate the immune system. This platform has applications in cancer and infectious disease. Its platform leverages gp96’s role as a natural molecular warning system that presents antigens to the immune system. HS-110 (viagenpumatucel-L) is its allogeneic cell line biologic product candidate in a series of immunotherapies designed to stimulate a patient’s T-cells to destroy cancer utilizing its gp96 platform. HS-130 is an allogeneic cell line engineered to express the extracellular domain of OX40 ligand fusion protein (OX40L-Fc), a costimulator of T-cells, with the potential to augment antigen-specific CD4+ T-cell and CD8+ T-cell responses when combined with its gp96 platform. It has also developed a COVID-19 vaccine program under its Zolovax, Inc. subsidiary that utilizes its gp96 platform to secrete SARS-CoV-2 antigens.
| ✔ FTSE | ✘ AAOIFI | ✔ DJIM |
✔ COMPLIANT
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Responses